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Abstract
Eight novel human polyomaviruses have been discovered since 2007. Prevalence rates and tissue tropism for the most
recent members HPyV 6, 7, 9, TSPyV and MWPyV are largely unknown. We used real-time PCR to determine the presence of
HPyV 6, 7, 9, TSPyV and MWPyV in feces (n = 263), urine (n = 189), blood (n = 161), respiratory swabs (n = 1385) and
cerebrospinal fluid (n = 171) from both healthy control children and children and adults undergoing diagnostic testing.
Whole genome sequencing was able to be performed on 9 MWPyV positive specimens. Novel polyomaviruses were only
detected in respiratory swabs and feces, with no detections of HPyV 9 in any sample type. MWPyV was found to be the most
prevalent novel polyomavirus, being detected in 18 (1.5%) respiratory specimens from symptomatic patients, 16 (9.8%)
respiratory sample from healthy control children, 11 (5.9%) fecal specimens from patient suffering gastrointestinal illness,
and in 13 (15.3%) of feces from healthy control children. MWPyV was found only in respiratory and fecal specimens from
children, the oldest being 9 years old. HPyV 6, 7, 9 and TSPyV were also detected in respiratory specimens and fecal
specimens at low prevalence (,1.3%). The majority of these detections were found in immunocompromised patients. Our
findings suggest that MWPyV can result in a subclinical infection, persistent or intermittent shedding, particularly in young
children. The other novel polyomaviruses were also found in respiratory and fecal specimens, but at lower prevalence and
most commonly in immunocompromised individuals.
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Introduction
In the last five years, eight new human polyomaviruses have
been discovered, predominantly through the use of next genera-
tion sequencing techniques. In 2007, the first two novel
polyomaviruses, WU and KI were identified in children suffering
from acute respiratory tract infections. [1,2] A year later, Merkel
cell polyomavirus (MCPyV) was identified in Merkel cell
carcinoma (MCC) tissue, with strong evidence suggesting MCPyV
genome integration triggers cell transformation in MCC. [3] In
2010, human polyomaviruses 6 (HPyV 6) and 7 (HPyV 7) were
discovered on the foreheads of healthy volunteers. [4] In the same
year another skin-associated polyomavirus, Trichodysplasia spi-
nulosa-associated polyomavirus (TSPyV) was isolated from the
face of an immunocompromised patient suffering from Tricodys-
plasia spinulosa. This condition is found exclusively in immuno-
compromised patients and leads to numerous follicular extensions
around the face and nose. [5] In 2011, human polyomavirus 9
(HPyV 9) was amplified from the blood sample of a renal
transplant patient using degenerative primers, [6] and in 2012
Malawi polyomavirus (MWPyV) was identified in a stool sample of
a healthy child. [7].
Recently, two other polyomaviruses were reported, provision-
ally named HPyV10 and MXPyV. HPyV10 was isolated from
condylomas on the buttocks of patients suffering a rare genetic
disorder known as warts, hypogammaglobulinemia, infections, and
myelokathexis (WHIM) syndrome. [8] MXPyV, like MWPyV, was
identified in stool samples from children suffering diarrhea in
Mexico. [9] The whole genomes reported for these viruses share at
least 94.6% sequence identity with the index MWPyV sequence
(MA095).
The first human polyomaviruses JC (JCPyV) and BK (BKPyV)
were discovered in 1971 and are well characterized, with JCPyV
and BKPyV infection generally occurring in early childhood
resulting in sub-clinical or a mild respiratory infection.[10–12]
After primary infection a low persistent infection is thought to
continue, possibly in the lymphoid, neuronal, kidney or hemato-
poietic tissues.[13–15] This persistent infection can reactivate in
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immunocompromised patients causing, in some cases, severe
clinical symptoms. Progressive Multifocal Leukoencephalopathy
(PML) occurs when JCPyV reactivates in immunocompromised
patients, causing a lytic infection of the oligodendricytes leading to
demyelisation within the brain that rapidly progresses to a fatal
outcome. [10,16] In bone marrow (BMT) and renal transplant
patients, reactivation of BKPyV in urogenital tissues may cause
hemorrhagic cystitis (HC) and nephropathy, which can lead to
graft rejection in up to 10% of kidney transplant recipients.
[17,18].
Numerous studies have investigated prevalence rates, basic
epidemiology, genome variability and the possible pathogenicity of
WUPyV, KIPyV and MCPyV,[19–27] however as yet little
similar data are available for HPyV 6,7,9, TSPyV and MWPyV
infections.[7–9,28] Given the potentially serious implications of
polyomavirus infections in immunocompromised populations, and
the possible role of these viruses in cell transformation, it is
important to further understand the biology and prevalence of
HPyV 6,7,9, TSPyV and MWPyV. In this study, we used real-
time PCR and DNA sequencing to investigate the presence of




An overview of specimens tested and associated basic demo-
graphic information is outlined in Table 1. Briefly, Blood
(n = 161), urine (n = 189), CSF (n = 171), feces (n = 263) and
respiratory samples (n = 1385) from a number of existing specimen
banks were tested retrospectively. These included specimens
obtained from healthy volunteers and symptomatic patients
undergoing routine diagnostic testing at Pathology Queensland,
Australia.
Respiratory samples. The respiratory specimens (n = 1232)
examined in this study were obtained from 1143 patients with
respiratory symptoms which had diagnostic specimens submitted
for testing to Pathology Queensland, Australia, between October
2006 and December 2008. The majority of these samples were
collected in 2008 with approximately equal numbers of specimens
from each month (80 samples per month). The respiratory
specimens consisted of 993 nasopharyngeal aspirates (NPA), 145
Bronchoalveolar lavage (BAL), 31 nose and throat swabs, 33
bronchial washing, 6 sputum, 2 lung tissues and 22 respiratory
specimens of unknown type. Specimens were from both immu-
nocompetent and immunocompromised adult and pediatric
patients (age range 0.02–92.4 years, mean 16.6 years, median
1.7 years and 36 with age not recorded). These patients presented
with symptoms consistent with both upper and lower respiratory
tract infection. These samples had previously been tested for
common respiratory viruses by routine diagnostic PCR – influenza
A and B (INF A & B), respiratory syncytial virus (RSV),
parainfluenza viruses 1, 2, 3, & 4 (PIV 1, 2, 3 & 4), adenoviruses,
human metapneumovirus (HMPV), human rhinoviruses (HRV)
and human bocavirus (HBoV) as previously described.[29–33].
Blood samples. Blood samples were obtained from 161
patients undergoing routine BKPyV, cytomegalovirus, or adeno-
virus testing, during October 2006 to December 2009. These
patients were aged 1.2–77.3 years (mean 45.42 years, median
49.97 and 10 of unknown age), comprising 125 immunocompro-
mised patients and 36 immunocompetent patients.
CSF samples. CSF samples were from 171 patients under-
going microbiological testing from March 2010 until December
2010 for suspected neurological disease. These patients were aged
0–92.6 years (mean 27.97, median 23.17, and 1 of unknown age).
Urine samples. Urine samples were from 189 patients
undergoing testing from January 2009 until September 2012.
These patients were aged between 0.03–62.5 years (mean 19.08,
median 16.33 and 6 of unknown age).
Fecal samples. Fecal specimens were collected from 185
patients with gastrointestinal illness and tested by antigen-based
assays for both rotavirus and adenovirus by Pathology Queensland
or Sullivan and Nicolaides Pathology, Brisbane, Australia, during
February 2011 until March 2012. Patients were aged between
0.07–94.8 years (mean 22.4 years, median 4.4 years and 66
specimens were from patients of unknown age).
Healthy control sample population. Two separate healthy
control sample populations were used in this study. The first,
healthy control sample population A comprised nasopharyngeal
aspirates from 75 healthy children without recent respiratory
Table 1. Study sample population details and their associated MWPyV, HPyV 6, 7 &9 and TSPyV detections.
Sample type Disease state
Age range (mean;
median; age
unknown) MWPyV n (%) HPyV 6 n (%) HPyV 7 n (%) TSPyV n (%) HPyV 9 n (%)
Respiratory n = 1232 Symptomatic 0.02–92.4 years
(16.6; 1.7; 36)
18 (1.5) 2 (0.16) 3 (0.24) 1 (0.08) 0
Respiratory n = 153 Healthy 0–17.2 years
(4.8; 2.1; 3)
14 (9.2) 0 0 0 0
Blood n = 161 Symptomatic 1.2–77.3 years
(45.4; 49.97; 10)
0 0 0 0 0
CSF n = 171 Symptomatic 0–92.6 years
(28.0; 23.17; 1)
0 0 0 0 0
Urine n = 189 Symptomatic 0.03–94.8 years
(19.1; 16.3; 6)
0 0 0 0 0
Feces n = 185 Symptomatic 0.07–94.8 years
(22.4; 4; 66)
9 (4.9)* 1 (0.5) 1 (0.5) 1 (0.5) 0
Feces n = 78 Healthy 0–7.46 years
(1.4; 1.2; 3)
10 (12.8) 0 0 1 (1.2) 0
*11 positive specimens collected, three from one patient tested three times over 5 days therefore only one positive specimen was used to calculate prevalence.
doi:10.1371/journal.pone.0062764.t001
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symptoms, undergoing endoscopy or colonoscopy. Specimens
were collected between June 2007 and February 2011. The
children ranged in age from 0.2–17.2 years (mean 8.3 years,
median 8.4 years and 0 of unknown age).
Healthy control sample population B consisted of paired throat
swabs and fecal specimens from 78 otherwise healthy children
recruited from the Emergency Department (with a non-infectious
presentation) or child care centers near the Royal Children’s
Hospital, Brisbane. Specimens were collected from September
2007 until June 2010, with children’s ages ranging from 0–7.46
years (mean 1.4 years, median 1.2 years and 3 of unknown age).
Both control populations excluded children with symptoms of
respiratory or gastrointestinal infections in the seven days prior to
collection. A follow-up phone call was made approximately 4 days
after specimen collection to record any respiratory or gastroen-
teritis symptoms post-specimen collection (follow-up clinical
information is not available for 17 participants in healthy control
population A and four participants in healthy control population
B). If respiratory or gastrointestinal symptoms were recorded in
the follow-up phone call, specimens where excluded from the
healthy control populations (six participants excluded from healthy
control population A and seven participants excluded from healthy
control population B).
Sample Processing
Total nucleic acids were extracted from 0.2 mL of blood, urine
and CSF using the QIAxtractor instrument and DX viral nucleic
acid reagents (Qiagen, Australia) according to manufacturer’s
instructions. To monitor the efficiency and reproducibility of DNA
extraction, samples were spiked with 104 copies of equine herpes
virus (EHV) DNA (PCR crossing point of 30 cycles) before DNA
extraction. [34] Samples providing a crossing point within 3 cycles
of 30 cycles were considered efficiently extracted and free of PCR
inhibitors. Samples failing this procedure were re-extracted.
Additional processing was required for respiratory swabs and
fecal specimens before extraction. Briefly, 2.0 mL of phosphate
buffered saline was added to each collection tube containing the
respiratory swab and vortexed vigorously before 0.2 mL was
removed for extraction. A 10 ml loop was used to create a fecal
suspension 1 mL of PBS, which was then vortexed and clarified by
centrifugation at 6,000 g before 0.2 mL was removed for
extraction.
To reduce testing costs, nucleic acids from each specimen type
were combined in 10610 pools for initial screening as previously
described. [35] Individual specimens in polyomavirus positive
pools were retested with a second assay specific for each
polyomavirus. This secondary assay was designed in a different
region of the polyomavirus genome. For specimens to be
considered polyomavirus positive, both assays had to produce a
positive amplification curve below 41 cycles. Limited sequence
data is currently available for the novel polyomaviruses tested for
in this study therefore some virus positive samples may potentially
have been missed due to sequence variation within primer and
probe targets.
Virus Detection
Pooled sample extracts were screened by real-time polymerase
chain reaction (rtPCR) assays for HPyV6, [36] HPyV7, [6,36]
TSPyV [5] and HPyV9 in a duplex format (Duplex format;
HPyV6A+HPyV9B and HPyV7E+TSPyVA) using previously
published assays, with primer and probes for each assay shown
in Table 2.
The HPyV9 testing was performed using two novel rtPCR
assays designed for this study. The HPyV9B assay the large T-
antigen, and was duplexed with the HPyV6A assay for sample
pool testing; HPyV9B assay targeted targeted VP1and was used to
test HPyV9A positive pools. These assays were designed using
Primer Express 2.0 software and HPyV9 sequences publicly
available on Genebank (accession HQ696595 accessed on 06
November 2012).
MWPyV testing was performed using two rtPCR assays. These
comprised a previously described method by Siebrase et al 2012
(MW ES107) [7] and a newly designed assay (MW-E) developed as
part of this study, targeting a conserved region of the MWPyV
VP1 gene (Table 2). Primers and probes for MW ES107 and MW-
E also have 100% homology to the VP1 sequences reported for
HPyV10 and MXPyV.
Briefly, the MW-E assay was designed using Primer Express 2.0
software and the two MWPyV whole genome sequences publicly
Table 2. Primer and probes used in screening and
confirmatory rtPCR assays.
Assay Target Primer (59 –39)
MW-E forward VP1 CATTGATGGACAGCCAATGG
MW-E reverse VP1 TCCTGGAAGAGGTTCTGTTCCTT
MW-E probe VP1 TGGGACTGATAATCAAGTACAGGATGTAACTGTGT
ES105 forward [7] LTag TGAGAAGGCCCCGGTTCT
ES106 reverse LTag GAGGATGGGATGAAGATTTAAGTTG




HPyV 6A reverse LTag CGCCTGAATGTTTTAAAGGAGAA




HPyV 6D reverse LTAg TCTGGGAAGCTTTTGAATTGGT




HPyV 7E reverse LTAg CCCCTCATACAGCATAAGGTTAGATT




HPyV 7D reverse VP2/3 TTCACTTCTTTTTGTAGCTCCTCAAG




TSPyV A reverse LTAg TGCTACCTTGCTATTAAATGTGGAG




TSPyV B reverse VP1 ATTACAGGTTAGGTCCTCATTCAAC
TSPyV B probe VP1 ACAGCAGTGACCAGGACAAGCCTACTTCTG
HPyV 9 A forward VP1 CTAGGGAACAATTTGAATATCAGGAA
HPyV 9 A reverse VP1 ATAGTGTCCAGATCTAGGCTCTGAAC
HPyV 9 A probe VP1 AAGTTAGGCTGAGGCGGGAGATAGGG
HPyV 9 B forward LTAg CTAGGGAACAATTTGAATATCAGGAA
HPyV 9 B reverse LTAg ATAGTGTCCAGATCTAGGCTCTGAAC
HPyV 9 B probe LTAg AAGTTAGGCTGAGGCGGGAGATAGGG
doi:10.1371/journal.pone.0062764.t002
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available on Genebank (accessions; MA095, NC_018102,
WD976, JQ898292.1 accessed on 08 August 2012). Analytical
sensitivities for the three assays developed as part of this study
(MW-E, HPyV9A and HPyV9B) were ,10 copies/ul of extract. A
common reaction mix was used for all polyomavirus rtPCR assays.
This consisted of 12.5 ml of Quantitect Probe PCR Mix (Qiagen,
Australia), 10 pmol of each primer, 4 pmol of each probe and
5.0 ml of template to make a 25.0 ml final reaction volume. The
rtPCR was performed on the Rotorgene 6000 or Rotorgene Q
(Qiagen, Australia) under the following conditions: 15 min
incubation at 95uC, followed by 45 cycles of 95uC for 15sec and
60uC for 1 min.
DNA Sequencing
Whole genome sequencing was performed using a series of
walking primers. Sequence data were aligned and manipulated
with Bioedit Sequence Alignment Editor version 7.0.9.0. [37]
Phylogenetic analysis was performed using a neighbour-joining
(NJ) analysis with 1000 bootstrap and the Tamura-Nei substitution
model in the (Mega 4.1) software package. [38] Whole genome
sequences produced from this study were compared to the four
published MWPyV whole genomes (accessions; MA095
NC_018102, WD976 JQ898292.1, HPyV10 JX262162.1, UC-
MXPyV JX259273.1 accessed on 20 November 2012).
Data Analyses and Approval
Statistical comparisons were performed using the two-tailed
fisher’s exact test.
This study, including the use of specimens from a number of
sources, was approved by the Queensland Children’s Health
Services Human Research Ethics Committee. Written informed
consent was obtained from the guardians of the healthy control
populations for extended virus testing. We received a waiver from
the need to obtain individual consent from the Ethics Committee,
in accordance with National Guidelines [39], for patients whose
stored specimens, originally submitted for routine diagnostic
testing, were used in this study.
Results
The results for HPyV 6, 7, 9, TSPyV and MWPyV screening in
the various sample types are presented in Table 1 and Table 3.
Polyomavirus detections were only found in respiratory and fecal
specimens, with the most frequently detected polyomavirus being
MWPyV. HPyV 9 was not detected in any specimen.
Polyomavirus Detections - Respiratory Specimens
In respiratory specimens, 18 (1.5%) of samples from the
symptomatic patients and 14 (9.2%) from the healthy control
children were positive for MWPyV (Table 1). All MWPyV positive
subjects were aged less than 10 years. Nearly all of the MWPyV
positive diagnostic specimens (16/18) had at least one respiratory
pathogen co-detected with MWPyV (Table 3); 9/16 had one co-
detection, 5/16 had two other viruses co-detected and 2/16 had
three other pathogens co-detected with MWPyV. Clinical
symptoms were available for 11 of the 18 MWPyV positive
patients. These included fever, febrile convulsions, cough, wheeze,
rhinorrhea, diarrhea, conjunctivitis and increased respiratory
effort. Four MWPyV positive respiratory specimens where from
immunocompromised children, all diagnosed with acute lympho-
blastic leukaemia (ALL) (Table 3).
For the remaining polyomaviruses, HPyV6, 7 and TSPyV were
detected in 2 (0.16%), 3 (0.24%), and 1 (0.08%) of diagnostic
respiratory samples, respectively. HPyV 6, 7 and TSPyV were not
detected in any respiratory specimens from the healthy children
sample population. The two respiratory specimens that were
positive for HPyV6 were both from adults and comprised a BAL
specimen from a male aged 48 years and a NPA from a female
aged 61 years. Both HPyV6-positive patients were immunocom-
promised; the female patient was neutropaenic and pre-BMT and
the male patient was HIV positive. In both of these patients
HPyV6 was the only virus detected in each specimen.
The three respiratory specimens that were positive for HPyV7
were from two symptomatic children and one immunocompro-
mised adult male. The symptomatic HPyV 7 positive children
were a BAL specimen from a 1 year old male with neutropaenic
fevers, and a BAL from a 13 year old female BMT recipient. The
positive sample from the adult was an NPA from an immuno-
compromised male 67 years of age, suffering from acute myleiod
leukaemia (AML). These samples were positive for HPyV7 only,
except for the sample from the 1 year old male, in which
adenovirus was also detected.
Polyomavirus Detections - Fecal Specimens
MWPyV positive fecal specimens comprised 11 (4.9%) symp-
tomatic fecal specimens and 10 (12.8%) specimens from the
healthy control group. Three of the symptomatic positive fecal
specimens were taken from the same patient over a five day
period; this was recorded as a single positive for prevalence
calculations. MWPyV-positive patients where from children aged
between 1 and 2 years, 2 months of age (6 patients of unknown
age). In the symptomatic specimens, 8/11 (72.7%) reported a
positive co-detection with either rotavirus or adenovirus (Table 3).
A single positive specimen was detected for each of HPyV6, 7
and TSPyV in the symptomatic sample population. No clinical
information was available for the HPyV6 positive patient. The
HPyV7 positive patient was female, 63 years of age, and a renal
transplant recipient. The TSPyV positive patient was female, aged
14 years, had ALL, and was a BMT recipient. One specimen was
positive for TSPyV in the healthy control sample population; a
one year old male (Table 4).
MWPyV detection was significantly (p = 0.0001) more common
in children younger than five years (34/1017) than in children
aged five years and older (4/425).
A total of 26 MWPyV positive specimens were detected in
healthy control populations (n = 217) which was significantly
higher than the 29 detections in symptomatic specimens
(n = 1417) using a two-tailed Fishers exact test (p = 0.0001).
Healthy Control Population B - Paired Respiratory and
Fecal Specimens
Control population B contained paired fecal and respiratory
specimens from 78 healthy children. MWPyV was detected in
both the fecal and respiratory specimens of 4 participants. In
addition, MWPyV was detected in 4 participants’ respiratory
swabs, but not in the paired fecal specimens, and in the fecal
specimen but not the respiratory specimen of 7 participants
(Table 4).
MWPyV Whole Genome Sequencing
Whole MWPyV genome sequence data were generated for only
nine of the MWPyV-positive samples (GenBank accession
numbers: KC549586, KC549587, KC549588, KC549589,
KC549590, KC549591, KC549592, KC549593, KC549594).
Although a total of 51 MWPyV positives samples were detected
in this study, the cycle threshold values for the majority of these
were high (average Ct value of 33, range 24.91–40.37). This is
Novel Polyomaviruses in Different Specimen Types
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consistent with low viral loads which are difficult to sequence
reliably, and we were unable to obtain quality sequence data over
the entire viral genome. A phylogenetic tree, including the four
previously published MWPyV whole genome sequences, is shown
Table 3. Individual polyomavirus detections for symptomatic patients, including available demographic information, PCR Ct
values, viral co-detections and clinical information.
Symptomatic respiratory specimens
Polyomavirus Sample Age (years) Sex Ct value Co-detections Clinical information
MWPyV NPA 4.21 M 28.87 HRV, HBoV ALL
MWPyV NPA 1.22 F 29.1
MWPyV NPA 3.80 M 29.27 PIV 3,HRV ALL
MWPyV NPA 2.01 M 29.17 Adenovirus, HRV Conjunctivitis
MWPyV NPA 0.54 F 30.81 HRV Gastroschisis, TPN dependent
MWPyV NPA 1.35 F 30.94 RSV, HRV Cough, diarrhea
MWPyV NPA 6.64 F 30.59 hMPV ALL
MWPyV NPA 0.60 F 31.5 hMPV, HRV Yellow rhinorhea
MWPyV NPA 1.71 M 33.13 HRV
MWPyV NPA 4.38 F 32.75 HRV ALL
MWPyV NPA 1.36 M 34.65 Adenovirus Febrile, cough, increased respiratory effort
MWPyV Aspirate 1.81 M 34.8 PIV 1, HRV, HBoV 2 days post unexplained seizures
MWPyV NPA 2.85 F 35.89 hMPV Febrile for 2+ days
MWPyV NPA 1.09 M 38.09 HRV Febrile convulsions
MWPyV NPA 0.14 M 35.19 PIV 3 Bronchiolitis
MWPyV NPA 1.77 M 37.11 PIV 3 & 4, AdenovirusPUO Febrile
MWPyV NPA 1.39 M 38.8 HRV CP, recurrent RTIs, respiratory distress, wheeze, rhinorrea
MWPyV NPA 5.03 M 35.57 Sotos syndrome, cough
TSPyV NPA 0.57 M 37.86 hMPV
HPyV6 Lavage Bronchus/RLL 48.2 M 39.17 Pre-BMT, Neutropenic
HPyV6 NPA 61.4 F 28.92 HIV
HPyV7 NPA 1.04 M 36.84 Adenovirus Neutropenic, fevers
HPyV7 NPA 67.2 M 35.9 AML
Symptomatic fecal specimens
Polyomavirus Sample Age (years) Sex Ct value Co-detections Clinical information
HPyV7 BAL 13.6 F 32.83 BMT
MWPyV Fecal 1.01 M 29.52 Rotavirus Diarrhea, cough
MWPyV Fecal 1.46 F 25.65 Rotavirus Chronic diarrhea
MWPyV Fecal n/a n/a 33.67 Rotavirus n/a
MWPyV Fecal n/a n/a 33.76 Rotavirus n/a
MWPyV Fecal n/a n/a 30.25 Adenovirus n/a
MWPyV Fecal n/a n/a 32.13 Adenovirus n/a
MWPyV Fecal n/a n/a 35.76 Adenovirus n/a
MWPyV Fecal n/a n/a 33.44 Rotavirus n/a
*MWPyV Fecal 1.21 M 29.58 ALL
*MWPyV Fecal 1.21 M 30.71 ALL
*MWPyV Fecal 1.20 M 28.99 ALL
TSPyV Fecal 14.4 F 31.77 BMT/ALL
HPyV6 Fecal n/a 36.68 Rotavirus n/a
HPyV7 Fecal 63.8 F 36 Renal transplant
*Same patient collected over 5 days.
ALL – acute lymphoblastic leukaemia, AML – acute myeloid leukaemia, BMT – bone marrow transplant, TPN – total parenteral nutrition, CP – cerebral palsy, PUO –
pyrexia of unknown origin, URTI – upper respiratory tract infection, HIV – human immunodeficiency virus.
doi:10.1371/journal.pone.0062764.t003
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in Figure 1. Overall homology between all 13 MWPyV genome
sequences ranged from 95.6 to 100%. Sequence homology of
greater than 99.6% was seen between all sequences except the
index case (MA095) from Malawi (95.6%). Notably, an 11 base
pair insertion (nucleotide position 171–181) within the non-coding
control region was noted in all sequences except the index case
MA095.
Discussion
We used rtPCR to measure the prevalence of five novel human
polyomaviruses, HPyV 6, 7, 9, TSPyV and MWPyV in blood,
urine, CSF, respiratory and fecal specimens from both healthy and
symptomatic populations. Unlike JCPyV and BKPyV, no evidence
was found of these novel polyomaviruses in blood, urine or CSF.
[19] In respiratory samples, MWPyV was found to be the most
prevalent novel polyomavirus; detected in 1.5% of respiratory
specimens from symptomatic patients and 9.2% of respiratory
specimens from our young healthy control children. This differs
from a previous study from Mexico showing a detection rate of
0.74% in nasal washes from children suffering respiratory
infections. [9].
We detected MWPyV in 4.4% of fecal specimens collected from
patients suffering gastroenteritis and 12.8% in healthy control
children, which is higher than the previously reported rates of
2.3%, 3.3%, and 0% from children with diarrhea in St Louis,
Missouri, [7] California (unspecified number of stool samples from
children not suffering diarrhea) and Chile. [9] In contrast to our
findings however, Yu et al (2012) reported a high detection rate of
12.5% in children suffering diarrhea in Mexico. We also detected
HPyV6, 7 and TSPyV in respiratory and fecal specimens, but at
low prevalence (,1%), confirming very recent publications that
reported HPyV6, 7, 9 and TSPyV in respiratory, urine and fecal
specimens from immunocompromised children in St Louis,
Missouri. [28] HPyV9 was not detected in any of our samples.
HPyV9 has been reported in the blood of renal transplant
recipients, and our inability to detect HPyV9 may reflect the
relatively small number of blood samples from immunocompro-
mised subjects in our study (n = 125).
Detection of MWPyV exclusively occurred in children younger
than 10 years of age, which follows the generally accepted
paradigm of polyomavirus infection occurring early in life. It is
therefore not surprising that children younger than five years of
age had significantly higher MWPyV detection rates than children
older than five years and adults.
Interestingly, detection of MWPyV was significantly higher in
the fecal and respiratory specimens of healthy children compared
to the symptomatic sample populations. This trend was also seen
in age matched control populations from children in Chile where
4.2% of control specimens were MWPyV positive, but none in
samples from children with diarrhea. It appears that infection with
MWPyV in young children can be asymptomatic, and given that
the majority (16/18) of MWPyV-positive respiratory specimens
Table 4. Individual polyomavirus detections for healthy control populations, including match fecal and respiratory specimens.
Healthy control population A
Polyomavirus Sample Age (years) Sex Ct value respiratory Ct value Fecal
MWPyV NPA 0.9 F 30.61 n/a
MWPyV NPA 9.7 M 34.03 n/a
MWPyV NPA 9.5 F 35.28 n/a
MWPyV NPA 1.1 M 35.98 n/a
MWPyV NPA 1 M 36.87 n/a
Healthy control population B
Polyomavirus Sample Age (years) Sex Ct value respiratory Ct value Fecal
MWPyV Nose and throat swab/fecal 2.09 M 30.54 34.77
MWPyV Nose and throat swab/fecal 1.76 M 29.99 30.95
MWPyV Nose and throat swab/fecal 1.2 M 31.96 33.33
MWPyV Nose and throat swab/fecal 1.76 M 34.6 ND
MWPyV Nose and throat swab/fecal 1.03 F 33.88 ND
MWPyV Nose and throat swab/fecal 1.48 M 35.64 33.72
MWPyV Nose and throat swab/fecal 0.84 M 35.83 ND
MWPyV Nose and throat swab/fecal 1.45 M 34.31 ND
MWPyV Nose and throat swab/fecal 1.31 M ND 32.58
MWPyV Nose and throat swab/fecal 0.64 M ND 32.68
MWPyV Nose and throat swab/fecal 1.17 F ND 33.62
MWPyV Nose and throat swab/fecal 1.62 F ND 31.01
MWPyV Nose and throat swab/fecal 1.71 M ND 33.34
MWPyV Nose and throat swab/fecal 1.21 F ND 32.62
TSPyV Nose and throat swab/fecal 1.32 M ND 36.35
ND – Not detected.
doi:10.1371/journal.pone.0062764.t004
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from symptomatic patients were co-detected with a least one other
respiratory pathogen, many identifications may be coincidental.
Likewise in our study, 8/11 MWPyV-positive diagnostic fecal
specimens were co-detected with either adenovirus or rotavirus.
This is similar to the high co-detection rates reported for WUPyV
and KIPyV infections in respiratory samples, and raises questions
about the clinical significance of these viruses in childhood acute
infectious disease. [40] Nonetheless, the detection of MWPyV in
matched fecal and respiratory specimens from healthy children
may suggest a fecal-oral mode of transmission for MWPyV, as
proposed for other human polyomaviruses. [41].
Currently there is very little known about sequence variation of
MWPyV globally. The Australian isolates from this study clustered
with the three existing isolates from the United States and Mexico.
The isolate from the index case originating in Malawi was
divergent from the Australian, US, and Mexican isolates. Notably,
sequence variation between the index case and the Australian
isolates was 5.3%, whereas only 0.4% variation was observed
between the Australian and North American isolates. While these
data are limited, they are suggestive of a geographical distribution
for MWPyV similar to that of BKPyV. Previous studies have
shown that associations between BKPyV genotypes and geo-
graphical locations (America, Asia, and Europe) are sufficiently
consistent that they can be used to trace human migration. [42] It
is likely that the high sequence homology observed for MWPyV
strains from Australia and the US may be because the samples
were from individuals of European descent having a common
ancestry. [42,43] An 11 bp insertion has been observed in the non-
coding control region of the North American MWPyV positive
isolates. [7,9] This insertion was also found in all the Australian
isolates. While the significance of this insertion is yet to be
determined, it is similar to insertions reported within the KIPyV
non-coding control region and it is postulated that may have some
effect on transcription factor binding sites. [44].
HPyV6, 7 and TSPyV were detected in both children and
adults, albeit at low prevalence. However, all detections in adults
were from immunocompromised patients. Interestingly, a recent
study of immunocompromised children also found a low
prevalence of HPyV6, 7, 9 and TSPyV in respiratory, fecal and
urine specimens collected longitudinally. [28] Previous studies
have hypothesised an increased prevalence of WUPyV and KIPyV
in immunocompromised populations, however most have failed to
demonstrate either an increased incidence or more severe clinical
symptoms for this patient group.[45–48] It should also be noted
that HPyV 6, 7 and TSPyV have all been detected on human skin
of healthy subjects, and that the possibility of contamination from
the skin during collection of the respiratory and fecal samples must
be considered.
Conclusions
In summary, the results show that MWPyV, but not HPyV 6, 7,
9, or TSPyV, can be detected occasionally in respiratory and fecal
specimens submitted for viral investigations. However, the high
rate of detection of MWPyV in samples collected from asymp-
tomatic age-matched controls confounds the interpretation of the
role of this virus in human disease. Like WUPyV and KIPyV, a
clear role in disease is not evident but further studies of samples,
particularly from immunocompromised patients, are warranted.
Our results also demonstrate that MWPyV may be shed
simultaneously both within the gastrointestinal and respiratory
tracts and may be indicative of a possible fecal-oral route of
transmission during early childhood.
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